CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Abstract
No effective therapy is available for unresectable soft-tissue sarcomas (STS). This unmet clinical need prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells derived from multiple STS histotypes in vitro and in immunodeficient mice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-0357
Entities
People
- Alberto Pisacane
- Alessandra Merlini
- Chiara Donini
- Dario Sangiolo
- Elisa Landoni
- Elisa Vigna
- Enzo Medico
- Erika Fiorino
- Franca Fagioli
- Gianpietro Dotti
- Giovanni Grignani
- Giulia Cattaneo
- Giulia Mesiano
- Ilenia Iaia
- Lidia Giraudo
- Lorenzo D'Ambrosio
- Loretta Gammaitoni
- Marco Basiricò
- Massimo Aglietta
- Ramona Rotolo
- Soldano Ferrone
- Sonia Capellero
- Valeria Leuci
- Ymera Pignochino
Organizations
- Harvard Medical School
- National Institutes of Health
- United States Department of Defense
- University of North Carolina
- University of North Carolina at Chapel Hill
- University of Turin